Inventor · disambiguated record
Jing Zhang
Also filed as: ZHANG JING · ZHANG JING-REN
25 granted patents·42 pending applications·351 citations·filing 1997–2025
96Inventor score
Files withWUHAN YZY BIOPHARMA CO LTD17SHANGHAI JUNSHI BIOSCIENCES CO LTD10UNIV TEXAS9SHANGHAI GREEN VALLEY PHARMACEUTICAL CO LTD5SHANGHAI ZHENGE BIOTECHNOLOGY CO LTD2
Top patents by PatentIndex Score
67 records- 0197US6719983B2VMP-like sequences of pathogenic BorreliaUNIV TEXAS·Filed 2002·Granted Apr 13, 2004·43 cites·19 claims
- 0295US9079965B2Bispecific antibodyWUHAN YZY BIOPHARMA CO LTD·Filed 2014·Granted Jul 14, 2015·47 cites·8 claims
- 0395US8071109B2VMP-like sequences of pathogenic BorreliaNORRIS STEVEN J·Filed 2010·Granted Dec 6, 2011·15 cites·10 claims
- 0494US7135176B2VMP-like sequences of pathogenic BorreliaUNIV TEXAS·Filed 2004·Granted Nov 14, 2006·30 cites·15 claims
- 0594US6740744B2VMP-like sequences of pathogenic borreliaUNIV TEXAS·Filed 2002·Granted May 25, 2004·30 cites·31 claims
- 0692US8354240B2VMP-like sequences of pathogenic BorreliaUNIV TEXAS·Filed 2011·Granted Jan 15, 2013·7 cites·5 claims
- 0791US6808888B2Universal nucleic acid amplification system for nucleic acids in a samplePRIMAGEN HOLDING BV·Filed 2002·Granted Oct 26, 2004·100 cites·26 claims
- 0890US6878816B2Vmp-like sequences of pathogenic BorreliaUNIV TEXAS·Filed 2002·Granted Apr 12, 2005·16 cites·28 claims
- 0988US10118964B2Construction and application of bispecific antibody HER2xCD3WUHAN YZY BIOPHARMA CO LTD·Filed 2017·Granted Nov 6, 2018·5 cites·6 claims
- 1088US9611325B2Construction and application of bispecific antibody HER2xCD3WUHAN YZY BIOPHARMA CO LTD·Filed 2015·Granted Apr 4, 2017·6 cites·4 claims
- 1188US6437116B1VMP-like sequences of pathogenic borreliaUNIV TEXAS·Filed 1997·Granted Aug 20, 2002·30 cites·48 claims
- 1287US9562110B2Bispecific antibodyWUHAN YZY BIOPHARMA CO LTD·Filed 2012·Granted Feb 7, 2017·10 cites·8 claims
- 1387US9212218B2Vmp-like sequences of pathogenic BorreliaUNIV TEXAS·Filed 2013·Granted Dec 15, 2015·2 cites·18 claims
- 1483US7785597B2VMP-like sequences of pathogenic BorreliaUNIV TEXAS·Filed 2006·Granted Aug 31, 2010·4 cites·8 claims
- 1582US10960066B2Streptococcus pneumoniae vaccineUNIV TSINGHUA·Filed 2019·Granted Mar 30, 2021·2 cites·10 claims
- 1678US12110329B2Anti-BTLA antibodySHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Granted Oct 8, 2024·1 cites·15 claims
- 1766US10858447B2Anti-PCSK9 antibody and use thereofJUNSHI BIOSCIENCES CO LTD·Filed 2016·Granted Dec 8, 2020·1 cites·20 claims
- 1866US2025115671A1Anti-ccr8 antibodies and methods of useBEIGENE LTD·Filed 2024·Application pending·0 cites
- 1965US2016266112A1Vmp-like sequences of pathogenic borreliaUNIV TEXAS·Filed 2015·Application pending·0 cites
- 2060US2020071421A1Bispecific antibodyWUHAN YZY BIOPHARMA CO LTD·Filed 2019·Application pending·0 cites
- 2160US2022332757A1Split intein and preparation method for recombinant polypeptide using the sameWUHAN YZY BIOPHARMA CO LTD·Filed 2020·Application pending·0 cites
- 2258US2025066491A1Novel markers for recombinant production systemSHANGHAI ZHENGE BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 2358US2005064478A1Universal nucleic acid amplification system for nucleic acids in a sampleFiled 2004·Application pending·0 cites
- 2458US2022340677A1Split intein and preparation method for recombinant polypeptide using the sameWUHAN YZY BIOPHARMA CO LTD·Filed 2020·Application pending·0 cites
- 2558US2024247043A1Lag-3 protein mutant, and preparation and use thereofWUHAN YZY BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 2657US2024117043A1Bispecific antibody targeting cd112r and tigit and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2023·Application pending·0 cites
- 2756US2025101402A1Selectable markers for eukaryotic expression systemSHANGHAI ZHENGE BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 2856US2025368740A1Multifunctional recombinant antibody, preparation method and use thereofSHENZHEN BAISHITONG TECH DEVELOPMENT COMPANY LIMITED·Filed 2022·Application pending·0 cites
- 2955US12331119B2Modified Fc fragment, antibody comprising same, and application thereofWUHAN YZY BIOPHARMA CO LTD·Filed 2019·Granted Jun 17, 2025·0 cites·8 claims
- 3055US2021338694A1Sos1 allosteric site targetingZHENG YI·Filed 2021·Application pending·0 cites
- 3155US2023080842A1Tetravalent symmetric bispecific antibodiesWUHAN YZY BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 3254US12324833B2Recombinant severe respiratory syndrome coronavirus 2 Rbd trimer protein vaccine capable of generating broad-spectrum cross neutralization activity, and preparation method and use thereofNAT VACCINE AND SERUM INSTITUTE NVSI·Filed 2021·Granted Jun 10, 2025·0 cites·20 claims
- 3354US11639388B2CD3 antigen binding fragment and application thereofWUHAN YZY BIOPHARMA CO LTD·Filed 2019·Granted May 2, 2023·0 cites·5 claims
- 3454US2017226222A1Bispecific antibodyWUHAN YZY BIOPHARMA CO LTD·Filed 2017·Application pending·0 cites
- 3554US2025002605A1Bispecific antibody and use thereofWUHAN YZY BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 3654US2025019454A1Anti-tnfr2 antibodies and uses thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Application pending·0 cites
- 3753US2023192854A1Anti-btla antibody pharmaceutical composition and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 3853US2025368751A1USE of Antibody Mutation FOR Therapeutic Antibody DrugSHENZHEN BAISHITONG TECH DEVELOPMENT COMPANY LIMITED·Filed 2022·Application pending·0 cites
- 3953US2025026820A1ANTI-TGFbeta ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOFWUHAN YZY BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 4052US2024309087A1Anti-cd112r antibody and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 4152US2025296962A1S-RBD Trimer Protein Vaccine for Novel Coronavirus and Preparation Method and Application ThereforNAT VACCINE AND SERUM INSTITUTE NVSL·Filed 2022·Application pending·0 cites
- 4252US2024425575A1Anti-ang2 antibody, preparation method therefor, and application thereofSOTER BIOPHARMA PTE LTD·Filed 2021·Application pending·0 cites
- 4351US2024052029A1Ror1-targeting antibody and use thereofBIOHENG THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 4451US2025127915A1Anti-cldn-18.2 antibody-drug conjugate and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 4550US7723086B2Apparatus for encapsulating cellsAGENCY SCIENCE TECH & RES·Filed 2004·Granted May 25, 2010·2 cites·31 claims
- 4650US2023212278A1Pharmaceutical composition of anti-il-17a antibodies and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 4750US2024067720A1Anti-tigit antibody pharmaceutical composition and application thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 4849US2024148850A1N protein epitope mutation marker for preparing epitope deletion-marked vaccine strain of type ii porcine reproductive and respiratory syndrome virus (prrsv) and use thereofLANZHOU VETERINARY RES INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES·Filed 2022·Application pending·0 cites
- 4949US2023192903A1Bispecific antibody against cldn18.2 and cd3WUHAN YZY BIOPHARMA CO LTD·Filed 2020·Application pending·0 cites
- 5049US2024117061A1Anti-bcma antibody, preparation method therefor and application thereofWUHAN YZY BIOPHARMA CO LTD·Filed 2020·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jing Zhang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →